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Targeting Apoptosis via Chemical Design:
Inhibition of Bid-Induced Cell Death
by Small Organic Molecules
teins such as cytochrome c and SMAC/DIABLO [8–10]
(Figure 1A).
The generation of Bid knockout mice has begun to
reveal the pathophysiological roles of this proapoptotic
protein in vivo. These mice are viable, lacking develop-
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La Jolla, California 92037 ment abnormalities. However Bid/ mice are resistant
to hepatic cell apoptosis and liver injury when injected
with antibodies directed against TNF-family death re-
ceptor Fas [11]. Mice lacking Bid also display resistance
Summary to brain injury in a stroke model involving transient mid-
dle cerebral artery occlusion [12]. In addition, recent
Bid is a key member of the Bcl-2 family proteins in- studies using transgenic mice models of amyotrophic
volved in the control of the apoptotic cascade in cells, lateral sclerosis (ALS) strongly suggest a pivotal role for
leading to cell death. Uncontrolled cell death is associ- Bid in the overall cascade of molecular events responsi-
ated with several human pathologies, such as neuro- ble for the onset and progression of this neurodegenera-
degenerative diseases and ischemic injuries. There- tive process [13]. Taken together, these results show
fore, Bid represents a potential yet unexplored and that Bid is a key molecule in the control of apoptosis
challenging target for strategies aimed at the develop- in vivo and suggest that it could be a molecular target
ment of therapeutic agents. Here we show that a multi- for treatment of pathologies associated with uncon-
disciplinary NMR-based approach that we named SAR trolled cell death.
by ILOEs (structure activity relationships by interligand While several small molecule inhibitors of antiapo-
nuclear Overhauser effect) allowed us to rationally de- ptotic members of the Bcl-2 family have been reported
sign a series of 4-phenylsulfanyl-phenylamine deriva- [14–22], so far no inhibitors have been discovered
tives that are capable of occupying a deep hydropho- against the proapoptotic members including Bid. Antag-
bic crevice on the surface of Bid. These compounds onists of antiapoptotic proteins Bcl-2 and Bcl-XL have
represent the first antiapoptotic small molecules tar- been based on targeting the site on these proteins re-
geting a Bcl-2 protein as shown by their ability to inhibit sponsible for binding BH3 peptides [14–19]. However,
tBid-induced SMAC release, caspase-3 activation, and an analogous strategy cannot be applied to Bid, as the
cell death. molecular basis for its function have not yet been char-
acterized. The three-dimensional structure of mouse
Bid, as elucidated by NMR spectroscopy [7, 23], revealsIntroduction
the presence of a deep hydrophobic crevice on the sur-
face of the protein in a region that is conserved betweenApoptosis is a crucial process for tissue homeostasis
mouse and human Bid, just adjacent to the BH3 peptidethat is controlled by the Bcl-2 family proteins, which
region. Taking advantage of a combined approach in-includes anti- and proapoptotic members [1–3]. Among
volving an NMR fragment-based screening, interligandthe proapoptotic proteins of this family are Bax-like pro-
nuclear Overhauser effect (ILOEs), molecular modeling,teins, whose aminoacid sequences show a high degree
and synthetic chemistry, we obtained compound BI-of similarity to the antiapoptotic family members, and
6C9 that is capable of binding into this crevice. We showBH3-only proteins, whose similarity to the Bcl-2 mem-
here that this binding results in loss of proapoptoticbers is limited to the BH3 region, a dimerizing motif
activity of Bid in vitro and in cells (Figure 1B). The datashared by essentially all family members [4]. Bid is a
obtained clearly demonstrate the ability of our approachwidely expressed member of the BH3-only proteins con-
that we named SAR by ILOEs (structure activity relation-sisting of 195 amino acid residues whose active form is
ships by interligand nuclear Overhauser effect), to tacklebelieved to be the 15 kDa N-truncated derivative (tBid)
challenging drug targets such as those involving pro-that results from caspase-8 cleavage of the full-length
tein-protein interactions.22 kDa protein [5, 6]. Caspase-8-mediated cleavage at
the Bid N-terminal region not only exposes the BH3
domain but also results in myristyolation of tBid, thus Results
prompting tBid to translocate from the cytosol to mito-
chondrial membranes where it integrates [7]. Once at Strategy
the outer mitochondrial membrane tBid interacts with To design small molecule compounds capable of occu-
multidomain proapoptotic proteins Bax and Bak, induc- pying the deep hydrophobic crevice on the surface of
ing their oligomerization in membranes of mitochondria Bid, we adopted a fragment-based approach. A tighter
and triggering changes in mitochondrial membrane per- chemical binder is built from pairs of compounds that
meability, which result in release of apoptogenic pro- bind to adjacent sites on Bid, using a small but diverse
library of molecular fragments [24, 25]. This library in-
cludes low molecular weight compounds (MW 300)*Correspondence: mpellecchia@burnham.org
1These authors contributed equally to this work. that represent a selection of the substructures fre-
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Figure 1. Bid-Induced Cell Death
(A) Apoptosis induced by caspase-8 medi-
ated Bid activation.
(B) Compounds capable of blocking tBid mi-
gration would result in cell survival.
quently found in drugs [26] and that are amenable to plished also in complex mixtures, where deconvolution
can be easily achieved aided by the NMR spectra ofsubsequent chemistry. Because the compounds have
very simple structures, a library of a few hundred deriva- individual compounds.
We prepared several mixtures of compounds from ourtives is typically sufficient to represent the diverse
frameworks. However, due to their limited size and con- library of scaffolds (0.4–0.9 mM each) and tested them
in presence of 10 M Bid (Figure 2A). Typical trNOESYsequent limited number of possible interactions with a
given protein, a few of the small fragments will exhibit spectra were measured with 8 or 16 transients per incre-
ment with mixing times of 300–800 ms, to maximize theat most low affinity for the target. For this reason, we
applied solution nuclear magnetic resonance (NMR) detection of trNOEs and ILOEs [32]. Pooling compounds
in mixtures of 6–24 allowed the collection of the spectraspectroscopy as screening method, since it allows the
detection of very weak binders [27]. for our 300 fragments library in a few days. Analysis of
the data and subsequent deconvolution of the spectraA valuable NMR-based technique to screen a library
of compounds and validate their binding to a target allowed us to identify weak ligands by means of positive
trNOEs crosspeaks. Similarly, compounds that bind Bidprotein is the measurement of transferred NOEs [24,
28, 29]. Since small molecules tumble rapidly in solu- in close proximity (less that 5 A˚) are identified by de-
tecting intermolecular NOEs (ILOEs) [31–35] serving astion, the dominant 1H relaxation mechanisms during a
NOESY-type experiment lead to weak, positive NOEs building blocks for producing linked compounds. As
depicted in Figures 2B and 2C, the experiments were(crosspeaks have opposite sign than diagonal peaks).
On the contrary, when the ligand is bound even tran- repeated for the pairs that were recognized to bind to
Bid, such as BI-2A1/BI-2A7 (Figure 2B) and BI-2A2/BI-siently to a target protein it assumes its long correlation
time. In the case of a rapid exchange between free and 2A7 (Figure 2C).
To identify the amino acids involved in this interaction,bound state (namely when koff  1/T1, the longitudinal
relaxation rate), this translates into very strong negative we prepared 15N-labeled Bid and acquired 2D [15N,1H]-
TROSY spectra in absence and presence of the weakNOEs (i.e., very strong positive crosspeaks in a NOESY-
type experiment). The use of 2D [1H,1H]-NOESY spectra binders [33, 36] (Figure 3A). As a result of the addition
of BI-2A7 to 15N-labeled Bid, several modification re-[30] is then obvious in the search for small molecular
binders. In a mixture of compounds in presence of a sulted in the [15N,1H]-TROSY spectrum of the protein and
analysis of the chemical shift perturbations, based onsubstoichiometric amount of target (Bid), only those
compounds that bind appreciably to the protein will the published resonance’s assignments [7], allowed us
to map the interactions with the ligand. The residuesexhibit strong negative NOEs, whereas nonbinders will
show no NOEs or at most very weak positive ones. In mostly affected by this binding were S28, A87, L105,
A137, G143, N144, K146, F171, L182, T185, and S184.addition, if two or more ligands bind simultaneously in
adjacent sites on the protein surface, strong negative The changes were plotted on the three-dimensional
structure of Bid and showed that most of the changesligand-ligand NOEs (ILOEs) can also be observed [31–
35]. Compounds that display ligand-ligand interactions fall in proximity of the deep hydrophobic groove on the
surface of the protein (Figure 3B, red areas).can then serve to design covalently linked compounds
with increased affinity [31–35]. We demonstrate here Once the interaction sites on the Bid surface were
identified by chemical shift mapping, we docked thethat the detection of such interactions can be accom-
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Figure 2. Intra- and Interligand-Based Identification of Small Compounds that Bind BID
(A) Spectrum of a mixture of 12 small molecules (0.4–0.9 mM each) in presence of Bid (10 M), with many NOE crosspeaks present.
(B) Spectrum of a solution of BI-2A1 and BI-2A7 in presence of Bid (10 M).
(C) Spectrum of a solution of BI-2A2 and BI-2A7 in the presence of Bid (10 M). In (B) and (C) ILOE crosspeaks between the two molecules
are circled.
two pairs of building blocks in the three-dimensional CDI) [38], using as starting materials the commercially
available 4-amino-4-nitrodiphenyl sulfide and the N-Bocstructure of the protein to envisage possible linkers be-
tween the two fragments. We focused initially on the amino acid (n  3 or n  5). Stirring the reaction mixture
at room temperature resulted in the corresponding Boc-pair BI-2A1/BI-2A7 since the resulting compounds were
synthetically more accessible. To prioritize the synthetic protected amines BI-6C6 and BI-6C12. Deprotection
with trifluoroacetic acid (TFA) gave the free amines BI-efforts, we relied heavily on in silico docking by using
FlexX [37] as implemented in Sybyl (TRIPOS, Inc.) fol- 6C7 and BI-6D1 in good yields (Figure 5A). Following
reaction with 4-methoxybenzenesulfonyl chloride affordedlowed by CSCORE analysis and visual inspection. We
docked several compounds and the chemical structures the corresponding sulfonamides BI-6C8 and BI-6D2 in
very high yields. The synthesis was completed by reduc-of eight of them are reported in Table 1 (first column)
together with the fragments BI-2A2, BI-2A1, and BI-2A7. ing the aromatic nitro group to the amines BI-6C9 and
BI-6D3 in presence of tin dichloride (SnCl2) [39].The best results in terms of fitting in the hydrophobic
groove were observed for BI-6C8 and BI-6C9 (Figure To examine the binding affinity of these bi-dentate
derivatives to Bid, we measured 2D [13C,1H]-HSQC spec-4A), whereas the corresponding 5-carbons linker deriva-
tives did not dock well. Therefore, by using a combina- tra in presence of 13C methionine-labeled protein, as
at least one methionine is present in the hydrophobiction of mixture-based trNOEs and ILOEs screening (SAR
by ILOEs), chemical shift mapping, and virtual docking, groove of Bid (Figure 4B). As described earlier, we ini-
tially evaluated the binding affinity of these compoundswe designed a first series of bi-dentate compounds tar-
geting the hydrophobic groove near the BH3 region of from chemical shifts induced upon titration. The results
are reported in Table 1 (column 2) and are qualitativelyBid (Figure 4B).
in good agreement with the predictions based on virtual
docking studies. Figure 5C shows the 2D [13C,1H]-HSQCSynthesis and Binding Studies
spectrum of 13C methionine-labeled Bid upon additionThe combined NMR and virtual docking approach re-
of BI-6C9. The binding of BI-6C9 appears to be slow onsulted in the design of compounds BI-6C8 and BI-6C9
the NMR timescale, as indicated by the appearance/as potential Bid antagonists. Nonetheless, we decided
disappearance of crosspeaks in the spectrum upon ti-to synthesize and evaluate the binding properties of
tration (Figure 5C). Monitoring the variation of cross-other derivatives to verify the validity of our approach.
peak intensity upon addition of increasing amounts ofThe synthesis of eight 4-phenylsulfanyl-phenylamine
BI-6C9, allowed us to estimate its dissociation constantderivatives is described in Figure 5A. Peptide bond for-
(KD 20 M, Figure 5D).mation was aided by resin-bound carbodiimide, such
To further confirm the binding of BI-6C9 into the crev-as N-cyclohexylcarbodiimide-N-propylmethyl polysty-
ice on the surface of Bid, we also performed T1 competi-rene (PS-CDI) (Argonaut Technologies) or 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (WS- tion experiments. In these experiments, the relaxation
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effects were obtained with 15N-Bid after cleavage with
caspase-8, leading to tBid [5, 6]. This observation sug-
gests that the truncated Bid protein is capable of binding
even better to our compound than full-length Bid.
In Vitro and Cell-Based Assays
We tested the two fragments and all the newly synthe-
sized compounds in vitro for their ability to inhibit Bid-
mediated release of SMAC using mitochondria isolated
from HeLa cells. Each compound was tested at a con-
centration of 50 M. As illustrated in Figure 6A, only BI-
6C9 was able to significantly reduce tBid-induced SMAC
release at this concentration. This compound was then
tested at several doses using the same mitochondria-
based assay, showing that it dramatically decreased
SMAC release at concentrations as low as 20M (Figure
6B). To preliminarily investigate the mechanism by which
BI-6C9 reduces SMAC release from isolated mitochon-
dria, we tested its effects on association of recombinant
tBid protein with mitochondria in vitro. Accordingly, the
tBid protein was treated with different concentrations of
BI-6C9, after which it was incubated with mitochondria,
followed by analysis of the bound and unbound fractions
by immunoblotting using Bid antibody. The concentra-
tion of mitochondria-bound tBid diminished in response
to increasing concentrations of BI-6C9. Dose-response
experiments showed that the compound is effective at
inhibiting tBid association with isolated mitochondria at
20 M (Figure 6C).
BI-6C9 was also evaluated for its ability to inhibit Bid-
induced apoptosis in cell. For these experiments, HeLa
cells were transfected with a plasmid encoding tBid, and
effector caspase activity was measured in cell lysates
24 hr later. BI-6C9 reduced caspase-3 activity in tBid-
transfected cells by4-fold at 50 M, whereas caspase
activity was totally blocked at 100M (Figure 6D). More-
over, tBid-induced cell death, as measured by caspase-3
activity, was reduced from 80%  5% to 35%  5% by
50 M BI-6C9 (Figure 6E).
As controls we verified that BI-6C9 does not bind
appreciably to other Bcl-2 family proteins such as Bcl-
Figure 3. Chemical Shift Mapping XL (NMR binding assay).
Finally, we have also determined that our compound(A) 2D [15N,1H]-TROSY spectrum measured with a sample of 0.5 mM
BID in the absence (black) and presence (red) of 1 mM BI-2A7. does not impair caspase-8-mediated Bid cleavage (by
Arrows indicate those resonances that are affected by the presence SDS page) and does not inhibit caspase-3 (in vitro assay)
of BI-2A7. at the concentrations used in the cellular assay (data
(B) Chemical-shift mapping and docking of BI-2A7 into the three-
not shown).dimensional structure of Bid (PDB code 1DDB). Regions affected
by the binding of BI-2A7 are highlighted in red. This and all other
figures showing the surface of Bid were generated by MOLCAD Discussion
[49]. The color code is according to cavity depth: blue, shallow;
yellow, deep.
Several evidences show that Bid plays a central role in
the apoptotic machinery mediating cytochrome c and
SMAC/DIABLO release from mitochondria, a crucialeffects detected on the 1H signals of compound BI-2A7
induced by the presence of Bid (10 M) are competed event for caspase activation and cell death [40] (Figure
1). Pharmacological inhibition of Bid could therefore pro-with small amounts of BI-6C9 (10 M) (data not shown).
Finally, we also performed chemical shift mapping vide a protective benefit against pathological cell death,
occurring in cerebral ischemia, neurodegenerative dis-using BI-6C9 and 15N-Bid. Although the shifts are not
very large, presumably due to the limited solubility of eases, liver inflammation, or other illnesses where Bid
has been implicated [12, 13, 41, 42].the compound at the concentrations (high micromolar)
needed for such experiments or because the complex By screening of a small library of compounds using
NMR, we isolated pairs of molecules that bind to adja-may be in the slow to intermediate exchange with re-
spect to 1H and 15N resonances, larger and more evident cent sites on Bid. Aided by computational modeling,
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Table 1. Chemical Structures and Assay Data
SMAC Release
Fitting in the Two NMR Inhibition at
Compound Structure Subpockets Binding 50 M (%)
BI-2A2 ND a ND
BI-2A1 ND a 0
BI-2A7 	 	 22
BI-6C6 		 		 14
BI-6C7 		 	 66
BI-6C8 				 			 24
BI-6C9 			 				 100
BI-6C12 		 ND 0
BI-6D1 		 ND 60
BI-6D2   16
BI-6D3  ND ND
Qualitative data in terms of docking (fitting in the two subpockets, column 1), chemical shifts in HSQC spectra (NMR, column 2), and in vitro
assays on isolated mitochondria (SMAC release inhibition, column 3) for the two fragments (BI-2A1 and BI-2A7) and the eight newly synthesized
compounds. Results are represented by plus and minus or by percentage of inhibition of SMAC release. ND, not determined.
a iLOEs with BI-2A7 were observed.
we identified possible linkers for covalently binding the general applicability and does not necessarily require
the knowledge of the three-dimensional structure or thepairs of compounds, thus arriving at high affinity bind-
ers. Note that, as anticipated by Fejzo et al. [24], Li et availability of isotopically (15N and/or 13C and/or 2H) la-
beled target. One could simply synthesize compoundsal. [32], and Kline [35], the fragment-based approach of
linking binders detected via trNOEs and ILOEs is of with linkers of different length and nature and test the
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sence of observable protons close to the sulfonic acid
group. In summary, while the use of ILOEs in the design
of bi-dentate compounds or to improve an existing lead
is an attractive application for drug discovery [21, 29], we
demonstrate here that a key element for the successful
implementation of such strategy is the optimal design
of the scaffold library for the detection of such interac-
tions by NMR.
As shown, our method (SAR by ILOEs) can be com-
bined with chemical shift mapping in the three-dimen-
sional structure of the protein target (if available) and
molecular modeling in the design of bi-dentate com-
pounds. Again, this is not an indispensable step, but
it can result in a reduced number of molecules to be
synthesized and tested.
Among the eight synthesized compounds, BI-6C9 was
found to be the strongest Bid binder, and in vitro it
dramatically reduced tBid-induced release of SMAC
from isolated mitochondria at concentrations as low as
20M (Figure 6B). Moreover, cell-based assays showed
that this compound effectively inhibits tBid-mediated
caspase activation and cell death already at concentra-
tions as low as 50 M.
The precise mechanism by which this compound in-
hibits the activity of Bid remains to be determined. Sev-
eral evidences support a role for the BH3 peptide region
of Bid as a critical effector of apoptosis, which binds
Bax and Bak, activating these proapoptotic proteins to
affect changes in mitochondrial membrane permeability
[44–46]. However, Bid is also capable of inserting in
membranes, possibly functioning as an ion channel [47].
We speculate here that occupancy of the hydrophobic
crevice of Bid or tBid by our compound either interferes
with exposure of the BH3 domain or blocks insertion of
tBid in membranes by maintaining Bid in an inactiveFigure 4. Virtual Docking of BI-6C9 into the Three-Dimensional
conformation.Structure of Bid
In conclusion, we have successfully utilized a combi-(A) BI-6C9 sits in the hydrophobic groove.
nation of NMR and virtual docking approaches to dis-(B) The hydrophobic groove is near to the BH3 peptide which is
highlighted in red. cover a small bi-dentate molecule capable of inhibiting
Bid in vitro and in cells. This compound could be useful
in deciphering the complex mechanism of action and
resulting compounds for binding and activity. Analysis cellular functions of Bid in apoptosis. Further optimiza-
of trNOEs and ILOEs build-up rates can also provide tion of BI-6C9 might result in compounds with improved
some structural information on the relative orientation affinity for Bid and favorable pharmaceutical properties
of the two fragments [32, 43]. However, for a successful that permit its testing in animal models of diseases, thus
implementation of this strategy, the library must be care- providing a starting point for development of potential
fully designed to optimize the detection of ligand-ligand drug candidates for human illnesses associated with
interactions by selecting compounds with appropriate uncontrolled cell death.
derivatizations of functional groups with proton NMR-
detectable substituents. Furthermore, the introduction
of heteroatoms in these substituents also results in large Significance
chemical shift dispersion between the compounds of the
library, thus enabling the detection of ILOEs in complex We have demonstrated that a multidisciplinary ap-
proach (SAR by ILOE) taking advantage of NMR-basedmixtures, as we reported here. For example, in com-
pound BI-2A1 (Table 1) the benzenesulfonic acid is de- fragment screening, molecular modeling, and syn-
thetic chemistry allowed us to rationally design a se-rivatized with a methylamine group. This enables on the
one hand the observation of trNOEs and ILOEs to its ries of 4-phenylsulfanyl-phenylamine derivatives that
are capable of occupying a deep hydrophobic crevicemethyl group and on the other it provides a scaffold
that chemically resembles more closely the bi-dentate on the surface of Bid. We have also demonstrated that
this binding results in inhibition of tBid-induced SMACcompound. Should one have used benzensulfonic acid
instead, not only the negative charge could have influ- release, caspase-3 activation, and cell death. As such,
our compounds could be useful in deciphering theenced the binding but the detection of trNOEs and, most
importantly, ILOEs, would have been limited by the ab- complex mechanism of action and cellular functions
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Figure 5. Chemical Synthesis, Virtual Docking of BI-6C9, and NMR Characterization of Kd
(A) Synthetic scheme for the bi-dentate ligands with 3- and 5-carbons linker.
(B) Docking of BI-6C9 into the three-dimensional structure of Bid. In red are highlighted the two methionines present in the hydrophobic
groove.
(C) 2D [1H,13C]-HSQC of 
-13C-Met Bid (200 M) in the absence (black) and presence (red) of 150 M BI-6C9. The arrow indicates the peak
that was monitored to determine the Kd for BI-6C9.
(D) Plot of the peak volume versus the concentration of BI-6C9. The peak volume was referenced to a peak that was unaffected by BI-6C9,
and the peak volume was plotted as the fraction of the maximum peak volume observed for saturation of Bid with BI-6C9.
their subsequent use as building blocks for the synthesis of bi-of Bid in the apoptotic cascade and provide a valuable
dentate compounds, eliminating fragments that would lead to teth-starting point for development of potential drug candi-
ered ligands with undesirable critical properties. The following crite-dates for human illnesses associated with uncon-
ria were adopted: average molecular weight 300, octanol/water
trolled cell death. Furthermore, the data obtained repartition coefficient (LogP) 1.3, and number of rotatable bonds
clearly demonstrate the ability of the SAR by ILOE between 0 and 2. The goal in using these empirical drug-like property
filters is to predict favorable outcome in ADME (adsorption, distribu-approach to tackle challenging drug targets. We antic-
tion, metabolism, excretion) studies, as well as final success asipate that possible future applications could include
drug in humans. In addition, availability of each fragment in largerthe design of potential antagonists of protein-protein
amounts at low cost as well as ease of synthesis and conversionand protein-nucleic acids interactions.
to more complex structures, were also taken into consideration in
selecting the scaffolds. Finally, our library was designed to optimize
Experimental Procedures the detection of trNOEs and ILOEs by selecting compounds with
appropriate derivatization of functional groups with proton NMR-
Library Design detectable substituents.
The NMR compound library is composed by 300 low molecular
weight compounds representing diverse core structures. This library
was assembled and individual 1D 1H spectra were measured in D2O Protein Expression and Purification
Recombinant full-length mouse Bid was produced from a pET-19bbuffer as control of compound purity, stability, and solubility in water
buffer. In designing the NMR library, particular emphasis was put (Novagen) plasmid construct containing the entire nucleotide se-
quence for Bid fused to an N-terminal poly-His tag. Unlabeled Bidinto the chemical properties of the selected compounds in an at-
tempt to address “drug likeness” on empirical grounds. In this re- was expressed in E. coli BL21 in LB media at 37C, with an induction
period of 3–4 hr with 1 mM IPTG. 15N-labeled Bid was similarlyspect, compounds with reactive functional groups such as halides,
anhydrides, epoxides, aziridines, phosphonate and sulphonate es- produced, with growth occurring in M9 media supplemented with
0.5 g/l 15NH4Cl. -13C-Met-labeled Bid was produced in M9 mediaters, imines, aldehydes, Michael acceptors, and halopyrimidines,
were not included. The compounds were also selected in view or supplemented with 50 mg/l of -13C-Met at time of induction with
Chemistry & Biology
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Figure 6. Suppression of tBid Activity In Vitro and in Cells by Bid Binding Compounds
(A) Effect of compounds on SMAC release from mitochondria isolated from HeLa cells. The first lane represents mitochondria incubated
without tBid. All others received 100 ng tBid without or with compounds.
(B) BI-6C9 blocks tBid-induced SMAC release from mitochondria isolated from HeLa cells.
(C) BI-6C9 blocks tBid association with mitochondria.
(D and E) BI-6C9 reduces tBid-induced caspase activation in 293T cells (D). BI-6C9 reduces tBid-induced cell death in 293T cells (E). a, GFP;
b, GFP 	 BI-6C9 100 M; c, GFP 	 BI-6C8 100 M; d, Z-VAD-fmk.
IPTG. Following cell lysis, soluble Bid was purified over a Hi-Trap a 500 or 600 MHz Bruker Avance spectrometer, both equipped with
TXI probes. Typical parameters for the 2D [15N,1H]-TROSY spectrachelating column (Amersham, Pharmacia), followed by ion-exchange
purification with a MonoQ (Amersham, Pharmacia) column. Final Bid included 1H and 15N /2 pulse lengths of 11 and 40 s, respectively;
1H and 15N sweep widths of 12 and 32 ppm, respectively; 16 scanssamples were dialyzed into a buffer appropriate for the subsequent
experiments. tBid was produced by cleavage of purified Bid with and 256 indirect acquisition points; and a recycle delay of 1 s. For
the 2D [13C,1H]-HSQC typical parameters included 1H and 13C /2caspase-8, as reported [47].
pulse lengths of 10 and 13 s, respectively; 1H and 13C sweep widths
of 12 and 5 ppm, respectively; 128 scans and 80 indirect acquisitionMolecular Modeling
points; and a recycle delay of 1 s. 2D [1H,1H]-NOESY spectra wereMolecular modeling studies were conducted on several R12000 SGI
typically acquired with eight scans for each of 400 indirect points,Octane workstations with the software package Sybyl version 6.9
a 1H /2 pulse length of 11 s, sweep widths of 12 ppm in both(TRIPOS). The docked structures of the compounds were initially
dimensions, mixing times of 300–800 ms, and a recycle delay of 1 s.obtained by FlexX [37] as implemented in Sybyl. Molecular models
In all experiments, dephasing of residual water signals was obtainedof compounds were energy minimized with MAXIMN2 (Sybyl). For
with a WATERGATE sequence.each molecule, 20 solutions were generated and ranked according to
CSCORE [48]. The solutions were finally ranked by visual inspection
of the linked compounds in the deep hydrophobic groove on the surface Chemistry
of Bid. Surface representations were generated by MOLCAD [49]. {3-[4-(4-Nitro-Phenylsulfanyl)-Phenylcarbamoyl]-Propyl}-
Carbamic Acid Tert-Butyl Ester (BI-6C6)
N-Cyclohexylcarbodiimide-N-propylmethyl polystyrene (PS-CDINMR Spectroscopy
For all NMR experiments, Bid was exchanged into 50 mM phosphate resin, 730 mg, 1.0 mmol) was added to a dry, round-bottomed flask.
t-Boc-4-aminobutanoic acid (152 mg, 0.75 mmol) was added as abuffer at pH 7.5 and measurements were performed at 30C. 2D
[15N,1H]-TROSY spectra for Bid were measured with 0.5 mM samples solution in CH2Cl2 (4 ml) and the reaction mixture was stirred at room
temperature. After 5 min, 4-amino-4-nitrodiphenyl sulfide (123 mg,of 15N-labeled Bid. 2D [13C,1H]-HSQC spectra were measured with
0.2 mM samples of -13C-Met-labeled Bid. 2D [1H,1H]-NOESY spectra 0.5 mmol) in 4 ml of CH2Cl2 was added and the suspension stirred
at room temperature for 4 days. The reaction mixture was filteredwere acquired with small molecules at a concentration of 0.9 mM
in the presence of 10 M BID. T1 competition experiments (200 ms under vacuum and the resin was washed twice with CH2Cl2. Concen-
tration of the filtrate afforded a crude that was purified by flashspin-lock duration) were performed on either 100 M BI-2A7 or a
mixture of 100 M BI-2A7 and 10 M BI-6C9, in the presence and chromatography (hexane/ethyl acetate 1:1) to give the pure BI-6C6
(274 mg, 64%) as a yellow solid, together with unreacted startingabsence of 10 M Bid. All experiments were performed with either
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material (25 mg, 20%). 1H NMR (d-DMSO, 500 MHz): 10.19 (s, 1H), min. The acid was evaporated at the rotary evaporator and the
8.13 (d, J  8.5 Hz, 2H), 7.78 (d, J  8.5 Hz, 2H), 7.55 (d, J  8.5 residue dissolved in CH2Cl2. The solution was extracted with a 1 M
Hz, 2H), 7.23 (d, J  8.5 Hz, 2H), 3.00–2.97 (m, 2H), 2.37–2.34 (m, solution of K2CO3 and water. The organic phase was dried over
2H), 1.73–1.70 (m, 2H), 1.39 (s, 9H). 13C NMR (d-DMSO, 125 MHz): Na2SO4 and concentrated under reduced pressure to give the crude
171.3, 155.6, 148.8, 144.7, 141.0, 135.9, 125.9, 124.2, 123.1, 121.7, BI-6D1 (280 mg, 78%) as a bright yellow solid. The compound was
77.4, 33.8, 29.2, 28.2, 27.1. used for the following step with no further purification. 1H NMR
4-Amino-N-[4-(4-Nitro-Phenylsulfanyl)-Phenyl]- (d-DMSO, 500 MHz): 10.16 (s, 1H), 8.13 (d, J  9.0 Hz, 2H), 7.78 (d,
Butyramide (BI-6C7) J  9.0 Hz, 2H), 7.55 (d, J  8.2 Hz, 2H), 7.24 (d, J  8.2 Hz, 2H),
Compound BI-6C6 (274 mg, 0.63 mmol) was added to a round- 2.56–2.54 (m, 2H), 2.37–2.36 (m, 2H), 1.63–1.60 (m, 2H), 1.39–1.34
bottomed flask and cooled to 0C. The minimum amount of trifluoro- (m, 4H). 13C NMR (d-DMSO, 125 MHz): 171.7, 148.8, 144.7, 141.1,
acetic acid needed to dissolve the compound was added and the 135.9, 125.8, 124.2, 123.1, 121.7, 41.4, 36.5, 32.8, 26.0, 24.9.
solution stirred at room temperature for an additional 5 min. The 6-(4-Methoxy-Benzenesulfonylamino)-Hexanoic Acid
acid was evaporated using a rotary evaporator and the residue [4-(4-Nitro-Phenylsulfanyl)-Phenyl]-Amide (BI-6D2)
dissolved in CH2Cl2. The solution was extracted with a 1 M solution A suspension of the amine BI-6D1 (280 mg, 0.78 mmol) and triethyla-
of K2CO3 and water. The organic phase was dried over Na2SO4 and mine (132 mg, 1.0 mmol) in 5 ml of CH2Cl2 was cooled to 0C and
concentrated under reduced pressure to give the crude BI-6C7 (170 4-methoxybenzebesulfonyl chloride (177 mg, 0.86 mmol) was added
mg, 81%) as a bright yellow solid. The compound was used with as a solution in 7 ml of CH2Cl2. After stirring 2 hr at 0C and overnight
no further purification. 1H NMR (d-DMSO, 500 MHz): 8.13 (d, J  at room temperature, the reaction mixture was washed with water
6.0 Hz, 2H), 7.78 (d, J  9.5 Hz, 2H), 7.55 (d, J  6.0 Hz, 2H), 7.23 and a saturated solution of NaCl in water. The organic phase was
(d, J  9.5 Hz, 2H), 2.61–2.58 (m, 2H), 2.40–2.39 (m, 2H), 1.70–1.67 dried over Na2SO4 and concentrated under reduced pressure to
(m, 2H). 13C NMR (d-DMSO, 125 MHz): 171.9, 148.8, 144.7, 141.1, afford BI-6D2 (368 mg, 90%) as a light yellow solid. 1H NMR (d-DMSO,
135.9, 125.8, 124.2, 123.1, 121.7, 41.1, 34.1, 29.0. 500 MHz): 10.14 (s, 1H), 8.13 (d, J  7.8 Hz, 2H), 7.79–7.72 (m, 4H),
4-(4-Methoxy-Benzenesulfonylamino)-N-[4-(4-Nitro- 7.54 (d, J  8.5 Hz, 2H), 7.23 (d, J  8.5 Hz, 2H), 7.11 (d, J  7.8,
Phenylsulfanyl)-Phenyl]-Butyramide (BI-6C8)
2H), 3.84 (s, 3H), 2.72–2.70 (m, 2H), 2.33–2.30 (m, 2H), 1.55–1.28 (m,
A suspension of the amine BI-6C7 (33 mg, 0.1 mmol) and triethyla-
6H). 13C NMR (d-DMSO, 125 MHz): 171.5, 161.9, 148.8, 144.7, 141.0,
mine (13 mg, 0.13 mmol) in 1 ml of CH2Cl2 was cooled to 0C and 135.8, 132.1, 125.9, 125.2, 124.1, 123.1, 121.7, 114.2, 55.5, 42.3,4-methoxybenzebesulfonyl chloride (23 mg, 0.11 mmol) was added
36.3, 28.7, 25.7, 24.5.as a solution in 1.5 ml of CH2Cl2. After stirring 2 hr at 0C and
6-(4-Methoxy-Benzenesulfonylamino)-Hexanoic Acidovernight at room temperature, the reaction mixture was washed
[4-(4-Amino-Phenylsulfanyl)-Phenyl]-Amide (BI-6D3)with water and a saturated solution of NaCl in water. The organic
To a suspension of BI-6D2 (100 mg, 0.19 mmol) in 4 ml of MeOHphase was dried over Na2SO4 and concentrated under reduced pres-
was added SnCl2 (213 mg, 0.94 mmol) and the mixture was refluxedsure to afford BI-6C8 (48 mg, 96%) as a light yellow solid. 1H NMR
for 5 hr. Methanol was then evaporated and a solution of 10%(d-DMSO, 500 MHz): 10.18 (s, 1H), 8.13 (d, J 9.0 Hz, 2H), 7.77–7.72
NaHCO3 was added carefully at 0C. The residue was extracted with(m, 4H), 7.55 (d, J  8.5 Hz, 2H), 7.50 (t, J  6.0 Hz, 1H), 7.23 (d,
ethyl acetate and the combined organic phases were dried overJ  9.0 Hz, 2H), 7.11 (d, J  8.5 Hz, 2H), 3.84 (s, 3H), 2.78–2.74 (m,
Na2SO4 and concentrated under reduced pressure to give BI-6D32H), 2.40–2.38 (m, 2H), 1.74–1.69 (m, 2H). 13C NMR (d-DMSO, 125
(80 mg, 84%) as a bright yellow solid. 1H NMR (d-DMSO, 500 MHz):MHz): 171.0, 162.0, 159.6, 159.5, 159.3, 157.5, 148.8, 140.9, 132.0,
9.82 (s, 1H), 7.72 (d, J  7.0 Hz, 2H), 7.45 (d, J  7.0 Hz, 2H), 7.38125.9, 124.2, 121.8, 114.2, 55.5, 41.9, 36.7, 32.0.
(bs, 1H), 7.14–7.02 (m, 6H), 6.60 (d, J  10.0 Hz, 2H), 5.42 (bs, 2H),N-[4-(4-Amino-Phenylsulfanyl)-Phenyl]-4-(4-Methoxy-
3.83 (s, 3H), 2.70–2.69 (m, 2H), 2.23 (bs, 2H), 1.51–1.25 (m, 6H). 13CBenzenesulfonylamino)-Butyramide (BI-6C9)
To a suspension of BI-6C8 (38 mg, 0.077 mmol) in 2 ml of MeOH NMR (d-DMSO, 125 MHz): 170.9, 161.9, 149.5, 137.1, 135.3, 132.7,
was added SnCl2 (85 mg, 0.38 mmol) and the mixture was refluxed 132.1, 127.8, 119.7, 116.3, 114.6, 114.4, 114.2, 55.5, 42.3, 36.1, 28.7,
for 5 hr. Methanol was then evaporated and a solution 10% NaHCO3 25.7, 24.5.
was added carefully at 0C. The residue was extracted with ethyl
acetate and the combined organic phases were dried over Na2SO4
and concentrated under reduced pressure to give BI-6C9 (27 mg, Experiments with Isolated Mitochondria
75%) as a dark yellow solid. 1H NMR (d-DMSO, 500 MHz): 9.84 (s, 100 ng of tBid (cleaved by caspase-8) was preincubated with various
1H), 7.70 (d, J  9.0 Hz, 2H), 7.46–7.43 (m, 3H), 7.13–7.07 (m, 4H), concentrations of compounds for 15 min at 30C in HM buffer (10
7.01 (d, J  8.5 Hz, 2H), 6.58 (d, J  9.0 Hz, 2H), 3.81 (s, 3H), mM HEPES, pH 7.4, 250 mM mannitol, 10 mM KCl, 1.5 mM MgCl,
2.73–2.69 (m, 2H), 2.29–2.26 (m, 2H), 1.67–1.63 (m, 2H). 13C NMR 1 mM DTT, 1 mM EGTA), then 50 g of isolated mitochondria from
(d-DMSO, 125 MHz): 170.4, 161.9, 149.4, 137.0, 135.3, 132.7, 131.9, HCT116 cells were added to a final volume of 50l in HM buffer. After
128.5, 127.8, 119.7, 116.4, 114.7, 114.2, 55.5, 42.0, 33.2, 24.8. 1 hr incubation at 30C, the samples were centrifuged at 10,000  g
{5-[4-(4-Nitro-Phenylsulfanyl)-Phenylcarbamoyl]-Pentyl}- for 5 min at 4C and the supernatant was analyzed by SDS-PAGE/
Carbamic Acid Tert-Butyl Ester (BI-6C12) immunoblotting using anti-SMAC antibody.
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (WS-
CDI resin, 422 mg, 2.2 mmol) was added to a solution of t-Boc-4-
aminobutanoic acid (509 mg, 2.2 mmol), 4-amino-4-nitrodiphenyl Cell-Based Assays
sulfide (493 mg, 2.0 mmol), and triethylamine (202 mg, 2.0 mmol) in
HEK 293T cells were transfected with 0.5 g of plasmids encoding
CH2Cl2 (6 ml). After 12 hr stirring at room temperature, the reaction either GFP or GFP-tBid in a 12-well plate. After 3 hr transfection,
mixture was washed with water, 6 N HCl, water, saturated NaHCO3 various compounds were added in DMSO to the media. After 20 hr ofsolution, and water. The organic layer was dried over Na2SO4 and
further incubation, cells were collected and either lysed for caspasethe solvent evaporated under reduced pressure to give BI-6C12 as
assays or fixed and stained with DAPI for determination of apoptosisa yellow solid (466 mg, 51%). 1H NMR (d-DMSO, 500 MHz): 10.15
[50]. For caspase activity assays, 293T cells were lysed in lysis(s, 1H), 8.13 (d, J  8.2 Hz, 2H), 7.78 (d, J  5.8 Hz, 2H), 7.55 (d,
buffer (10 mM HEPES, pH 7.4, 142.2 mM KCl, 5 mM MgCl2, 0.5 mMJ 5.8 Hz, 2H), 7.24 (d, J 8.2 Hz, 2H), 2.93–2.91 (m, 2H), 2.35–2.33
EDTD, 0.5% NP-40) containing a protease inhibitor mixture (Roche(m, 2H), 1.62–1.59 (m, 2H), 1.38 (s, 9H), 1.30–1.25 (m, 4H). 13C NMR
Molecular Biochemicals). The lysates were normalized for protein(d-DMSO, 125 MHz): 171.6, 159.4, 155.5, 148.8, 144.7, 141.0, 135.9,
concentration (10 g), then incubated with 100 M DEVD-AFC. En-125.9, 124.2, 121.7, 77.2, 36.4, 29.2, 28.2, 25.9, 24.7.
zyme activity was determined by the release of AFC fluorescence6-Amino-Hexanoic Acid [4-(4-Nitro-Phenylsulfanyl)-
and Vmax was calculated (mean  SD; n  3). For DAPI staining,Phenyl]-Amide (BI-6D1)
293T cells were fixed, washed with PBS, and stained with 0.1 mg/mlCompound BI-6C12 (460 mg, 1.0 mmol) was added to a round-
DAPI. The percentage of GFP-positive cells with apoptotic morphol-bottomed flask and cooled to 0C. The minimum amount of trifluoro-
ogy (fragment nuclei or condensed chromatin) was determinedacetic acid needed to dissolve the compound was added and the
solution let under stirring at room temperature for an additional 5 (mean  SD; n  3).
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